GI Windows has created a novel technology designed to create the same anastomosis performed in a surgical procedure, but with the lowered costs and invasiveness of an endoscopic (or non-surgical) intervention. The GI Windows procedure is intended to be done on a same-day, outpatient basis, and with no surgical incisions.
The company’s innovation creates an anastomosis using a slender, linear device, that can be loaded in the channel of a standard endoscope or a thin conduit, such as a catheter or needle. As the device is deployed from the scope or catheter, it self-assembles to form a large, octagonal shape.
When 2 of these devices are deployed in adjacent hollow organs, the devices join together and form a compression anastomosis, without the need for staples, sutures, or surgical access.
The GI Windows invention leverages the science already demonstrated with compression-based anastomotic techniques. This approach uses the body’s own healing processes to remodel tissue between two structure to form an anastomosis between two structures. With the GI Windows technology, this anastomosis can be large, patent, and created without surgical access.
This invention has a wide range of therapeutic applications, as anastomoses are currently performed in metabolic, biliary, and oncology procedures. Currently these therapies are primarily served with surgical interventions.
In metabolic surgical procedures, small-bowel bypasses are associated with durable weight loss and co-morbidity resolution. These effects are caused by limiting the absorption of ingested fats and carbohydrates, and by changes in gut hormones, triggered by the bypass of ingested food. Gut hormones can reduce appetite, slow gastric emptying, and increase the sensitivity to and production of insulin, in response to a glucose load in the blood.
Patients with type 2 diabetes suffer from insulin resistance, often brought on by excess adipose tissue, and in particular, visceral fat. Clinically significant and sustained weight loss has been shown to improve insulin resistance and in some patients, cure type 2 diabetes.
There is an enormous, unmet clinical need for a non-surgical, effective and lasting therapy to treat type 2 diabetes and obesity. The GI Windows technology has the promise to address this need.
1: Ikramuddin S, Korner J, Lee WJ, Connett JE, Inabnet WB, Billington CJ, Thomas AJ, Leslie DB, Chong K, Jeffery RW, Ahmed L, Vella A, Chuang LM, Bessler M, Sarr MG, Swain JM, Laqua P, Jensen MD, Bantle JP. Roux-en-Y gastric bypass vs intensive medical management for the control of type 2 diabetes, hypertension, and hyperlipidemia: the Diabetes Surgery Study randomized clinical trial. JAMA. 2013 Jun 5;309(21):2240-9.
2: Mingrone G, Panunzi S, De Gaetano A, Guidone C, Iaconelli A, Leccesi L, Nanni G, Pomp A, Castagneto M, Ghirlanda G, Rubino F. Bariatric surgery versus conventional medical therapy for type 2 diabetes. N Engl J Med. 2012 Apr 26;366(17):1577-85.